Australian regenerative medicine company Orthocell is teaming up with Johnson & Johnson’ s DePuy Synthes Products to carry out trials analyzing Ortho-ATI ® (autologous tenocyte implantation) therapy for regenerating degenerate tendons and ligaments. The multicenter study in Australia is expected to start during Q1 2017, led by Professor Allan Wang, at the University or college of Western Australia. Professor Wang is current chief executive of the Shoulder and Elbow Society of Australia. “ This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technologies, ” commented Paul Anderson, Orthocell’ s managing movie director.

Ortho-ATI is an autologous cell therapy, that involves expanding patient’ s own healthy tendon tissue in the laboratory and injecting them back into the broken tendon. Orthocell claims the product is the first autologous cellular therapy for tendon and ligament repair and revitalization that has been licensed in the Australia, New Zealand, the Oughout. S., Europe, China, and Japan. The treatment is already obtainable in Australia and New Zealand for treating tendon accidental injuries in patients who still have symptoms after conservative treatment plans, such as exercise programs or corticosteroid injections.

Orthocell has separately developed and started commercialization associated with Ortho-ACI ® (autologous chondrocyte implantation), an autologous chondrocyte cell product for treating broken cartilage tissue. The firm’ s CelGro ® collagen scaffold platform has been developed with regard to applications in tissue reconstruction and repair.